Treatment Outcomes in Psoriatic Arthritis

This chapter examines registry findings on the outcomes of patients with psoriatic arthritis and axial spondyloarthritis who transitioned from TNF inhibitors to IL-17A inhibitors. It explores the safety and efficacy of IL-17 treatments, addressing concerns such as gastrointestinal symptoms, mild adverse effects, and the importance of interdisciplinary collaboration.